Reprogramming bone endothelial cells for use in bone angiogenesis and osteogenesis
AssigneeMax-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
InventorsRalf H. Adams, Anjali Kusumbe, Saravana Ramasamy
Life of this patent
Estimating the term…
Abstract
The present invention relates to a factor for reprogramming bone endothelial cells to promote bone angiogenesis and osteogenesis as well as to an ex vivo method for reprogramming a bone endothelial cell to achieve cells able to mediate bone angiogenesis and osteogenesis. The subtype of bone endothelial cells mediating bone angiogenesis and osteogenesis express CD31 and Endomucin as markers.
Claims15
A factor generating type H bone endothelial cells for use in promoting bone angiogenesis and osteogenesis.
An ex vivo method for reprogramming a type L bone endothelial cell to a type H endothelial cell comprising the step of:
- increasing the stability or biological activity of HIF-1α in an isolated cell or activating Notch-signaling in said isolated cell.
Method for isolating bone endothelial cells able to mediate bone angiogenesis and osteogenesis.
Use of CD31 and Endomucin as marker for a type H bone endothelial cells which mediate growth of bone vasculature.
A method of determining a subtype of bone endothelial cells mediating growth of bone vasculature, comprising:
- measuring the expression level CD31 and Endomucin in a bone endothelial cell, wherein an increased CD31 and Endomucin expression level is indicative for the subtype of bone endothelial cells mediating growth of bone vasculature.
Dependencies are inferred from the claim text.